Defining incentives and counterincentives to reduce environmental pollution from the manufacturing of antibiotics
In this project we will describe the incentives and counterincentives for different actors along the pharmaceutical production chains with regards to limit antibiotic pollution, and suggest management options.
Project supported by CARe 2017- involving Joakim Larsson, Sverker Jagers, Fredrik Carlsson and Christian Munthe as principal investigators.
Environments polluted by discharges from antibiotic production are hot spots for the development of multi-resistant bacteria. Major discharges of antibiotics are documented for several countries, while specific legislation limiting such discharges are, in principle, lacking. Lack of transparency in the production chains limits incentives for pharmaceutical companies to put pressure on subcontractors providing active ingredients. Generic substitution systems, present in many countries, favor low price exclusively, providing counterincentives to invest in green production technology. Environmental risk assessments required during registration of medicinal products do not assess risks with discharges from production. In this project we will describe the incentives and counterincentives for different actors along the pharmaceutical production chains with regards to limit antibiotic pollution, and suggest management options.
Page Manager: Webbredaktionen|Last update: 5/19/2016